

Press Release

Heerlen (NL), 12 April 2022

DSM - repurchase of shares (4-8 April 2022)

Royal DSM, a global purpose-led science-based company, has repurchased 173,491 of its own shares in the period from 4 April 2022 up to and including 8 April 2022 at an average price of €162.36. This is in accordance with the repurchase program announced on 10 March 2022, covering the commitments for the final stock dividend 2021 and share based compensation plans. The consideration of this repurchase was €28.2 million.

The total number of shares repurchased under this program since 10 March 2022 to date is 888,583 shares for a total consideration of €141 million.

For more detailed information see '[Daily transaction details Share Repurchase Program announced 10 March 2022](#)'.

DSM

Royal DSM is a global, purpose-led company in Health, Nutrition & Bioscience, applying science to improve the health of people, animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

Or find us on:    

For more information

DSM Media Relations
Gareth Mead
tel. +31 (0) 45 5782420
email media.contacts@dsm.com

DSM Investor Relations
Dave Huizing
tel. +31 (0) 45 5782864
email investor.relations@dsm.com

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.